Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
Akihiko ShimomuraYasuaki SagaraRyo KotoMasakazu FujiwaraYuka KanemuraHiroshi KitagawaShigehira SajiPublished in: Breast cancer (Tokyo, Japan) (2024)
Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.
Keyphrases
- end stage renal disease
- early breast cancer
- newly diagnosed
- ejection fraction
- healthcare
- primary care
- chronic kidney disease
- prognostic factors
- papillary thyroid
- cardiac surgery
- electronic health record
- peritoneal dialysis
- patients undergoing
- case report
- locally advanced
- machine learning
- squamous cell carcinoma
- big data
- squamous cell
- acute kidney injury
- young adults
- lymph node metastasis
- childhood cancer
- patient reported